Skip to main content
PLRZ
NASDAQ Industrial Applications And Services

Polyrizon Partners with Clearmind Medicine to Develop Intranasal Neuroplastogen Formulation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.05
Mkt Cap
$19.813M
52W Low
$2.88
52W High
$2,235
52W Position info
353% above low
Off High info
99% below high
Rel. Volume
Market data snapshot near publication time

PLRZ has more than doubled off its 52-week low of $2.88.

Summary

Polyrizon Ltd. has entered a development agreement with Clearmind Medicine Inc. to formulate an intranasal version of Clearmind's MEAI drug candidate, leveraging Polyrizon's proprietary delivery platform.


Key Events · M&A and Partnerships · PLRZ

  • New Development Agreement Signed

    Polyrizon entered into a development agreement with Clearmind Medicine Inc. to create an intranasal formulation of Clearmind's MEAI drug candidate, a non-hallucinogenic neuroplastogen.

  • Validation of Intranasal Delivery Platform

    The collaboration leverages Polyrizon's proprietary intranasal technology, designed for enhanced residence time, targeted delivery, and optimized patient usability, validating its potential for third-party drug development.

  • Focus on CNS Conditions

    The intranasal MEAI formulation is intended for use in treating addiction-related and other central nervous system (CNS) conditions, aiming for potential advantages over oral administration.


Analysis · PLRZ · Industrial Applications And Services

This agreement validates Polyrizon's intranasal drug delivery technology by securing a partnership with a clinical-stage biopharmaceutical company. While specific financial terms were not disclosed, the collaboration positions Polyrizon as a key partner for specialized intranasal drug delivery, potentially opening new revenue streams and advancing its platform's application beyond its own product pipeline. The development of an intranasal MEAI formulation could offer advantages like faster absorption and lower effective doses for CNS conditions, supporting Clearmind's future clinical programs.

At the time of this filing, PLRZ was trading at $13.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $2.88 to $2,235.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLRZ - Latest Insights

PLRZ
Jul 02, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.80
Real-time Price: $12.25 info
Change: -$1.55 (-11%) info
Market Cap: $25.529M info
PLRZ
Jul 02, 2026, 7:32 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.30
Real-time Price: $12.25 info
Change: -$2.05 (-14%) info
Market Cap: $25.529M info
PLRZ
Jun 29, 2026, 8:44 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.48
Real-time Price: $12.25 info
Change: +$0.770 (+7%) info
Market Cap: $25.529M info
PLRZ
Jun 17, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.23
Real-time Price: $12.25 info
Change: -$0.980 (-7%) info
Market Cap: $25.529M info
PLRZ
Jun 15, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.70
Real-time Price: $12.25 info
Change: +$1.55 (+14%) info
Market Cap: $25.529M info